CD274 and breast cancer: So far, although the response to immunotherapy is not common in ER-positive BC, a study has defined a new immune feature in PD-L1-negative ER-positive BC patients, which indicates that such BC patients are more likely to benefit from immune checkpoint and histone deacetylase inhibition [14].